Insulin resistance: mechanisms of metabolic dysfunction and intervention targets

Insulin resistance — defined as impaired cellular response to insulin signalling leading to reduced glucose uptake and suppression of hepatic glucose production — is the central metabolic defect in type 2 diabetes and a defining feature of metabolic syndrome. It precedes overt hyperglycaemia by years to decades and drives a spectrum of downstream pathology including cardiovascular disease, non-alcoholic fatty liver disease, polycystic ovary syndrome, and accelerated cognitive decline.

Understanding insulin resistance at the molecular level is essential for evaluating the mechanisms of interventions across the metabolic research space — including the GLP-1 receptor agonists, MOTS-c, and NAD+ pathway compounds covered elsewhere on this site.

The normal insulin signalling cascade

Insulin resistance is best understood against the background of normal signalling. When insulin binds the insulin receptor (IR):

1. IR undergoes autophosphorylation on tyrosine residues in its intracellular kinase domain
2. Insulin receptor substrate proteins (IRS-1, IRS-2) are recruited and phosphorylated on tyrosine residues
3. Tyrosine-phosphorylated IRS-1/2 recruits PI3K, activating it
4. PI3K generates PIP3 at the inner plasma membrane
5. PIP3 recruits PDK1, which phosphorylates and activates Akt (protein kinase B)
6. Akt phosphorylation drives multiple downstream effects:
   • GLUT4 translocation to the plasma membrane (glucose uptake in muscle and adipose)
   • Suppression of gluconeogenic gene expression in the liver (PEPCK, G6Pase)
   • Activation of glycogen synthesis via GSK3 inhibition
   • Suppression of lipolysis in adipose tissue

Insulin resistance represents impairment at one or more steps in this cascade, with the most commonly studied defect being reduced IRS-1 tyrosine phosphorylation.

Mechanism 1: ectopic lipid and ceramide accumulation

The most experimentally robust cause of skeletal muscle and hepatic insulin resistance is ectopic lipid accumulation — specifically diacylglycerols (DAG) and ceramides accumulating in non-adipose tissues.

Diacylglycerol and PKCε/PKCθ: Intramyocellular DAG activates protein kinase C epsilon (PKCε) in the liver and PKCθ in skeletal muscle. These serine/threonine kinases phosphorylate IRS-1 at serine residues (rather than the activating tyrosine residues), triggering proteasomal degradation of IRS-1 and blocking downstream signalling. This DAG→PKC→serine phosphorylation of IRS-1 is the best-characterised single mechanism of insulin resistance in skeletal muscle.

Ceramide: Saturated fatty acids (particularly palmitate) drive ceramide synthesis via the de novo pathway. Ceramides activate PP2A (protein phosphatase 2A), which dephosphorylates Akt, and activate PKCζ, which sequesters Akt away from its membrane-activating location. Both mechanisms reduce Akt activity independently of upstream IRS-1 signalling.

The clinical implication: ectopic fat deposition — driven by caloric excess, reduced mitochondrial oxidative capacity, or adipose dysfunction — is a direct causal intermediary between obesity and insulin resistance.

Mechanism 2: mitochondrial dysfunction

Skeletal muscle insulin resistance is consistently associated with reduced mitochondrial oxidative phosphorylation capacity, reflected in decreased mitochondrial copy number, reduced electron transport chain complex activity, and impaired fatty acid oxidation.

Reduced mitochondrial capacity creates a metabolic bottleneck: fatty acids that cannot be fully oxidised accumulate as DAG and ceramide intermediates. This connects mitochondrial dysfunction to ectopic lipid accumulation as a unified pathophysiological circuit.

Mitochondrial fission/fusion imbalance: Insulin-resistant muscle shows increased mitochondrial fragmentation (fission) relative to fusion, producing smaller, less efficient mitochondrial networks. The fission-promoting proteins DRP1 and FIS1 are upregulated; the fusion-promoting proteins MFN1/2 and OPA1 are downregulated.

The mitochondria-targeted interventions covered in the SS-31 article and MOTS-c article address this component directly — MOTS-c in particular activates AMPK and promotes mitochondrial biogenesis in skeletal muscle in a way mechanistically relevant to insulin resistance.

Mechanism 3: inflammatory signalling

Adipose tissue in obesity secretes elevated pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and chemokines that recruit macrophages. Adipose macrophages in obese individuals shift toward the M1 (pro-inflammatory) phenotype.

TNF-α activates IKKβ and JNK, both of which phosphorylate IRS-1 at serine residues — the same inhibitory modification driven by DAG/PKC, converging on the same molecular target through different upstream triggers.

IKKβ also activates NF-κB, which drives expression of additional inflammatory genes — creating a self-amplifying loop. This inflammatory component explains the overlap between metabolic syndrome and systemic inflammatory conditions, and why anti-inflammatory interventions can improve insulin sensitivity.

Fetuin-A: A hepatokine elevated in insulin-resistant states, fetuin-A acts as an endogenous ligand for TLR4, activating the same TLR4→IKKβ/JNK→IRS-1 serine phosphorylation pathway as inflammatory cytokines. Elevated fetuin-A connects hepatic dysfunction directly to peripheral insulin resistance.

Mechanism 4: endoplasmic reticulum stress

The endoplasmic reticulum (ER) is the primary site of protein folding and lipid synthesis. In obesity, the ER is subjected to excess demand combined with reduced folding capacity — triggering the unfolded protein response (UPR).

Key UPR effectors — IRE1α, PERK, and ATF6 — converge on JNK activation and IRS-1 serine phosphorylation, linking ER stress to the same molecular endpoint as inflammatory and lipid-mediated mechanisms. ER stress also activates inflammatory gene expression through NF-κB, further amplifying the inflammatory component.

Mechanism 5: epigenetic dysregulation

In type 2 diabetes, multiple genes in the insulin signalling pathway show aberrant DNA methylation and histone modification patterns:

• Promoter hypermethylation of PPARGC1A (encoding PGC-1α, the master regulator of mitochondrial biogenesis) in diabetic skeletal muscle — consistent with the mitochondrial dysfunction above
• Reduced histone acetylation at GLUT4 gene regulatory regions in insulin-resistant adipocytes
• Altered SIRT1 expression affecting deacetylation of PGC-1α and FOXO transcription factors

This epigenetic dimension connects insulin resistance to the ageing biology discussed in the NAD+/sirtuin article — SIRT1's deacetylase activity is NAD+-dependent, linking cellular NAD+ levels to both metabolic gene expression and insulin sensitivity.

Tissue-specific heterogeneity

Insulin resistance is not homogeneous across tissues:

• Skeletal muscle: DAG/PKCθ and mitochondrial dysfunction are dominant; responsible for most postprandial glucose disposal impairment
• Liver: DAG/PKCε and inflammatory cytokines predominate; responsible for failure to suppress hepatic glucose output
• Adipose tissue: Inflammation and lipolysis dysregulation; elevated NEFA release amplifies ectopic lipid accumulation in other tissues
• Brain: Impaired hypothalamic insulin signalling contributes to dysregulated appetite and autonomic glucose control; relevant to Alzheimer's disease research

Peptide and metabolic intervention targets

The molecular mechanisms identify specific intervention points:

AMPK activation: Metformin, MOTS-c, and exercise all activate AMPK, which reduces malonyl-CoA and increases fatty acid oxidation — directly addressing ectopic lipid accumulation. MOTS-c's AMPK activation in skeletal muscle is covered in the MOTS-c metabolic adaptation article.

GLP-1 receptor signalling: GLP-1 RAs improve insulin sensitivity through weight loss (reducing ectopic lipid burden), direct anti-inflammatory effects, and hepatic glucagon suppression. The GLP-1 cardiovascular outcomes article contextualises the downstream benefits.

NAD+/SIRT1 restoration: SIRT1 deacetylates PGC-1α (promoting mitochondrial biogenesis) and IRS-2 (improving hepatic insulin signalling). NAD+ precursor supplementation supports SIRT1 activity in a mechanistically relevant direction for insulin resistance.

Summary

Insulin resistance is a multi-mechanism disorder converging on impaired IRS-1 and Akt activation in target tissues. The principal drivers — ectopic DAG/ceramide accumulation, mitochondrial dysfunction, inflammatory cytokine signalling, and ER stress — are interconnected and mutually amplifying. Epigenetic dysregulation at key metabolic genes provides a further layer of impairment that explains why insulin resistance progresses with age. Effective intervention targets multiple nodes simultaneously, which explains why lifestyle modification (addressing both ectopic lipid and inflammation) outperforms single-mechanism pharmacological approaches in reversal of early metabolic syndrome.